Zollinger-Ellison Syndrome (Pancreatic Tumor): Symptoms, Causes, and Treatment

What is Zollinger-Ellison Syndrome (Pancreatic Tumor)?

Zollinger-Ellison syndrome (ZES) is a rare condition where one or more tumors form in your pancreas or the upper part of your small intestine (duodenum). These tumors, called gastrinomas, secrete large amounts of the hormone gastrin, which causes your stomach to produce too much acid. The excess acid leads to peptic ulcers, diarrhea, and other symptoms.

ZES can occur at any age but is most often diagnosed between ages 30 and 60. It may be sporadic (occurring randomly) or associated with an inherited genetic syndrome called multiple endocrine neoplasia type 1 (MEN1).

Source: Mayo Clinic, National Institutes of Health (NIH)

Common Causes

Zollinger-Ellison syndrome is caused by gastrin-secreting tumors (gastrinomas). While the exact cause of these tumors is often unknown, several conditions and factors are associated with their development:

• Sporadic gastrinomas: Most cases (about 75%) occur randomly without a clear cause.
• Multiple endocrine neoplasia type 1 (MEN1): An inherited genetic disorder that increases the risk of tumors in the endocrine glands, including the pancreas and duodenum. About 25% of ZES cases are linked to MEN1.
• Pancreatic neuroendocrine tumors (PNETs): Tumors that arise from hormone-producing cells in the pancreas.
• Duodenal tumors: Gastrinomas may also develop in the duodenum (the first part of the small intestine).
• Genetic mutations: Changes in genes like MEN1 can lead to uncontrolled cell growth and tumor formation.
• Chronic inflammation: Long-term inflammation in the digestive tract may contribute to tumor development.
• Environmental factors: Exposure to certain chemicals or toxins (though specific links are not well-established).
• Family history: A family history of MEN1 or ZES increases the risk.
• Other endocrine tumors: People with tumors in other endocrine glands (e.g., parathyroid, pituitary) may be at higher risk.
• Unknown factors: In many cases, the cause remains unidentified.

Source: National Cancer Institute (NCI), Centers for Disease Control and Prevention (CDC)

Associated Symptoms

The excess stomach acid produced in Zollinger-Ellison syndrome leads to a variety of digestive symptoms. Common signs and symptoms include:

• Severe peptic ulcers: Painful sores in the lining of the stomach, duodenum, or esophagus. These ulcers may not respond to typical treatments.
• Abdominal pain: Often severe and persistent, usually in the upper abdomen.
• Diarrhea: Frequent, watery stools due to excess acid interfering with digestion.
• Heartburn or acid reflux: A burning sensation in the chest or throat.
• Nausea and vomiting: Often due to irritation from excess stomach acid.
• Bleeding in the digestive tract: May lead to black, tarry stools or vomiting blood.
• Weight loss: Due to poor nutrient absorption or reduced appetite from pain.
• Fatigue: Often caused by anemia from chronic bleeding or malnutrition.
• Loss of appetite: Due to persistent discomfort or pain.

In some cases, symptoms may be mild or mistaken for other conditions like gastroesophageal reflux disease (GERD) or irritable bowel syndrome (IBS).

Source: Johns Hopkins Medicine, World Health Organization (WHO)

When to See a Doctor

Zollinger-Ellison syndrome is rare, but you should seek medical attention if you experience any of the following:

• Severe or persistent abdominal pain that doesn’t improve with over-the-counter medications.
• Frequent diarrhea that lasts more than a few days.
• Unexplained weight loss.
• Black, tarry stools or vomiting blood (signs of gastrointestinal bleeding).
• Peptic ulcers that don’t heal with standard treatment or recur frequently.
• Heartburn or acid reflux that is severe or doesn’t respond to antacids or proton pump inhibitors (PPIs).
• A family history of MEN1 or Zollinger-Ellison syndrome.

Early diagnosis and treatment can help prevent complications like perforated ulcers, severe bleeding, or malnutrition.

Source: Cleveland Clinic

Diagnosis

Diagnosing Zollinger-Ellison syndrome involves a combination of blood tests, imaging studies, and endoscopic procedures. Here’s how doctors typically evaluate the condition:

1. Blood Tests

• Gastrin levels: High levels of gastrin in the blood are a key indicator of ZES. However, other conditions (e.g., kidney disease, use of PPIs) can also elevate gastrin.
• Stimulation tests: A secretin stimulation test may be used to confirm ZES. Secretin (a hormone) is injected, and gastrin levels are measured. In ZES, gastrin levels rise significantly.

2. Imaging Studies

• CT scan or MRI: To locate tumors in the pancreas or duodenum.
• Endoscopic ultrasound (EUS): A thin, flexible tube with an ultrasound probe is inserted into the digestive tract to visualize tumors.
• Octreotide scan: A radioactive tracer is injected to help identify neuroendocrine tumors.

3. Endoscopic Procedures

• Upper endoscopy: A scope is used to examine the stomach and duodenum for ulcers or tumors. Biopsies may be taken for further analysis.

4. Genetic Testing

• If MEN1 is suspected, genetic testing may be recommended to check for mutations in the MEN1 gene.

Source: National Center for Biotechnology Information (NCBI), Mayo Clinic

Treatment Options

Treatment for Zollinger-Ellison syndrome focuses on reducing stomach acid production, managing symptoms, and addressing the underlying tumors. Options include:

Medical Treatments

• Proton pump inhibitors (PPIs): Medications like omeprazole or pantoprazole are used to reduce stomach acid and heal ulcers.
• H2 blockers: Drugs like famotidine or ranitidine may be used if PPIs are ineffective.
• Octreotide: A synthetic hormone that can reduce gastrin secretion in some cases.
• Surgery: Removal of tumors (if localized and not metastatic) can cure ZES in some cases. Surgery may also be needed to treat complications like perforated ulcers.
• Chemotherapy or targeted therapy: For advanced or metastatic gastrinomas, treatments like chemotherapy or targeted drugs (e.g., everolimus) may be used.

Home and Lifestyle Management

• Avoid foods that trigger acid reflux, such as spicy foods, caffeine, alcohol, and fatty foods.
• Eat smaller, more frequent meals to reduce stomach acid production.
• Quit smoking, as it can worsen ulcers and acid reflux.
• Manage stress through relaxation techniques, as stress can exacerbate symptoms.
• Stay hydrated, especially if diarrhea is a persistent issue.

Source: American Society of Clinical Oncology (ASCO), American Gastroenterological Association (AGA)

Prevention Tips

Since the exact cause of Zollinger-Ellison syndrome is often unknown, prevention can be challenging. However, the following steps may help reduce risk or manage symptoms:

• Genetic counseling: If you have a family history of MEN1 or ZES, consider genetic testing and counseling to assess your risk.
• Regular screenings: If you have MEN1, regular screenings for tumors can lead to early detection and treatment.
• Avoid known triggers: Limit alcohol, tobacco, and foods that increase stomach acid.
• Manage chronic conditions: Properly treat conditions like GERD or peptic ulcers to reduce complications.
• Healthy lifestyle: Maintain a balanced diet, exercise regularly, and manage stress to support overall digestive health.

Source: CDC Office of Genomics and Precision Public Health

Emergency Warning Signs

Seek immediate medical attention if you experience any of the following symptoms, which may indicate a life-threatening complication:

• Severe abdominal pain that is sudden and intense (could indicate a perforated ulcer).
• Vomiting blood or material that looks like coffee grounds.
• Black, tarry stools (a sign of gastrointestinal bleeding).
• Signs of shock, such as rapid heartbeat, dizziness, or fainting (due to severe bleeding).
• Severe dehydration from persistent vomiting or diarrhea (e.g., extreme thirst, dry mouth, little or no urination).
• Difficulty breathing or chest pain (could indicate a severe ulcer complication).

These symptoms require emergency care. Call 911 or go to the nearest emergency room.

Source: UK National Health Service (NHS), American Red Cross